Kriadex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kriadex

Property Description
Active ingredient Clonazepam (INN)
Form Oral tablets, Orally disintegrating tablets
Pharmacological class Benzodiazepine, Anticonvulsant
General purpose CNS stabilization, reducing neuronal excitability
Origin Synthetic

Kriadex is a pharmaceutical preparation whose sole active ingredient is the synthetic compound Clonazepam (INN). This compound is classified as a high-potency benzodiazepine, belonging to the broader Anticonvulsant pharmacological class. Clonazepam is considered an essential medicine, a status that reflects its clinical role in managing neurological conditions. This product is a single-ingredient product, formulated for oral delivery. Clonazepam is classified as a long-acting agent, a distinction that indicates a sustained therapeutic effect compared to shorter-acting benzodiazepines.


Kriadex's Composition and General Purpose

The active ingredient, Clonazepam, is formulated with solid pharmaceutical excipients for systemic administration via the oral route, available as both conventional oral tablets and specialized orally disintegrating tablets (wafers). The drug's general purpose relates to its ability to modulate overactivity in the Central Nervous System (CNS) by selectively enhancing the inhibitory effect of the neurotransmitter, Gamma-aminobutyric acid (GABA). Clonazepam acts as an allosteric modulator of GABA-A receptors, thereby facilitating nerve signal inhibition. This core mechanism promotes CNS stabilization and reduces neuronal excitability, which is clinically used for controlling rapid, involuntary nerve signals.

Regulatory References

  1. WHO Essential Medicines
  2. essential medicine

What side effects are possible with Kriadex?

Possible side effects and safety information

The safety profile of Kriadex (Clonazepam) is defined by its actions as a Central Nervous System (CNS) depressant, leading to several officially documented adverse reactions. These effects are classified by regulatory authorities based on their frequency and the physiological systems affected.

Frequency-Classified Adverse Reactions

The most frequently observed adverse reactions are generally related to CNS depression. According to official labeling, Somnolence (drowsiness), Sedation, Fatigue, and Ataxia (impaired coordination) are classified as Very Common. Adverse effects categorized as Common include Dizziness, Depression, Memory impairment, Confusion, Headache, Muscle weakness, Slurred speech (Dysarthria), Nausea, and Constipation.

Serious Regulatory Safety Concerns

Official documents highlight several serious safety concerns. These include the substantial risk of Abuse, Misuse, Addiction, and Physical Dependence, which increases with dose and duration of treatment. Furthermore, a major warning exists for Respiratory Depression and the risk of Coma or Death, particularly when the medicine is used at the same time as Opioids or other CNS depressants. The drug is also associated with an increased risk of Suicidal Behavior and Ideation as an Antiepileptic Drug (AED).

Specific Safety Considerations

Safety notes specify that effects like sedation are often most prominent at the start of treatment and may lessen with continued use. Use is formally Contraindicated in individuals with a known sensitivity to benzodiazepines, in patients with severe hepatic disease, and in those with untreated acute narrow-angle glaucoma. Regulatory information also notes that older adults may experience increased sensitivity to sedative effects, which can elevate the risk of falls and injury.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Kriadex (clonazepam) overdose centers on manifestations of Central Nervous System (CNS) depression, which are documented as dose-dependent. Overdose presentations typically include somnolence, mental confusion, impaired coordination (ataxia), slurred speech, and reduced reflexes.

Severe Outcomes and Emergency Action

Classification Official Regulatory Statement
Life-Threatening Risks Documented severe outcomes include respiratory depression, hypotension, coma, and potential death. The risk is significantly increased when co-ingested with other CNS depressants, particularly alcohol or opioids.
Emergency Help Required Seek immediate medical attention (or call emergency services) if the individual is unresponsive, collapsed, having a seizure, or experiencing trouble breathing.

Supportive Management

Official management protocols emphasize symptomatic and supportive treatment, including maintaining a patent airway and supporting ventilation. The antidote, Flumazenil, is available but its use is restricted due to regulatory cautions, such as its contraindication in suspected mixed overdoses. Observation in a medical setting may be required to monitor vital signs and neurological status, particularly in older adults who may experience increased drowsiness and confusion.

Therapeutic Uses of Kriadex

What Kriadex Treats: Main Uses and Benefits

Kriadex is commonly used across conditions characterized by periods of heightened symptoms related to symptoms of increased neurological or muscular activity. It is generally applied in clinical settings that involve acute or unstable symptom patterns where supportive symptom management is appropriate.


The medication is used in situations involving certain distressing symptoms, including the management of various seizure disorders (such as akinetic, myoclonic, and absence seizures), panic disorder marked by recurrent unexpected attacks, and involuntary motor symptoms like Restless Legs Syndrome. It is applied across domains where additional symptomatic support is needed.

Quick Fact

Quick Fact: Relief for Symptoms of Heightened Physiological Activity


In clinical scenarios where symptoms escalate temporarily, Kriadex helps address symptom clusters that may become intense or disruptive. As a patient-oriented benefit, it contributes to easing the overall symptom load on patients’ daily lives. This is especially true in chronic conditions, where symptom stabilization is important.

“It is commonly used to help patients cope more steadily with difficult episodes and supports general comfort during symptomatic periods.”

The medication may assist with maintaining a sense of stability when symptoms are more noticeable, providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Kriadex

Kriadex (clonazepam) eligibility is strictly defined by regulatory authorities based on age, specific medical conditions, and physiological status.

Classification Population Restriction Status
Absolute Contraindications Patients with a known sensitivity to benzodiazepines or significant/severe liver disease (hepatic insufficiency). Contraindicated
Patients with acute narrow angle glaucoma, severe respiratory insufficiency, or myasthenia gravis. Contraindicated
Age-Related Rules Approved for adults (panic disorder and seizure disorders) and children 10 years and older (seizure disorders). Established Use
Older adults require careful dosage selection, usually starting low, due to increased sensitivity and potential organ impairment. Conditional Use
Condition-Specific Caution Use requires caution in patients with renal impairment, mild to moderate liver impairment, or chronic pulmonary insufficiency. Conditional Use
Pregnancy/Lactation Use during pregnancy only if the benefit outweighs the risk; excreted into human milk, requiring a decision to discontinue the medicine or breastfeeding. Restricted/Conditional

Eligibility is not established for the treatment of panic disorder in patients under 18 years of age. These rules define the boundaries for the medicine’s use according to government-approved labeling.

What should I know about interactions with other medicines?

Kriadex Interactions with other medicines and products

Kriadex (clonazepam) is a central nervous system (CNS) depressant, and its interaction profile is dominated by the risk of enhanced CNS depression when combined with other substances that produce similar effects. This pharmacodynamic interaction can lead to severe adverse outcomes.

The most serious interaction is with Opioids (e.g., pain or cough medicines containing opioids). Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Regulatory guidance strongly advises reserving this combination for cases where alternative treatment options are inadequate, requiring the lowest effective dosages and close monitoring for respiratory issues.

Other Interacting Categories

Category Interaction Mechanism & Outcome
Alcohol and Other CNS Depressants (e.g., muscle relaxants, some antidepressants, sedating antihistamines) Enhanced CNS Depression leading to increased drowsiness, sedation, dizziness, and impaired cognitive and motor performance. Concurrent use should be avoided.
Antiepileptic Drugs (AEDs): Specifically Phenytoin Pharmacokinetic Effect: Clonazepam has the potential to influence the plasma concentrations of phenytoin. Monitoring of phenytoin levels is recommended when these two medicines are co-administered.
Antiepileptic Drugs (AEDs): Carbamazepine, Phenobarbital Clonazepam does not appear to alter the pharmacokinetics or serum concentrations of carbamazepine or phenobarbital.

Patients should inform their healthcare provider of all prescription medicines, over-the-counter products, and herbal supplements currently being taken to properly assess and manage any potential interactions.

Mechanism of Action

Modulation of Inactivated Voltage-Gated Sodium Channels

Kriadex acts primarily by its active metabolite, eslicarbazepine, to modulate voltage-gated sodium channels ( VGSCs) on neuronal membranes. The drug specifically binds to the inactivated state of these channels, which are more prevalent during periods of high-frequency firing. This process limits the sustained inward current of Na^+ ions necessary for action potential generation.


Regulation of Neuronal Membrane Excitability

This molecular binding initiates a cascade that directly influences the Neuronal Excitability Pathway. By limiting the availability of VGSCs in the conducting state, the drug's mechanism leads to the stabilization of the neuronal membrane potential. This action results in a reduction in the amplitude and frequency of electrical signaling across neuronal networks in the Central Nervous System (CNS).


Reduced Propagation of High-Frequency Neuronal Activity

The overall effect of this state-dependent channel blockade is the reduction in action potential propagation. The modulation of sodium channel availability limits the propagation of sustained electrical activity across neuronal networks. This physiological change results from the drug's influence on core electrical conductance mechanisms.

Dosage and Administration Information

How to use Kriadex (Clonazepam) — Official Administration Guidelines

Kriadex is an oral medication that must be taken exactly as prescribed, typically divided into two or three doses daily, with or without food. The administration schedule is dependent on the condition being treated and the patient's age and weight.

Route of Administration and Preparation

  • Tablets: Swallow the tablet whole with water. Do not crush, chew, or split standard tablets.
  • Orally Disintegrating Tablets (ODTs): Peel back the foil (do not push the tablet through) and immediately place the tablet in the mouth using dry hands. The ODT will dissolve quickly and can be swallowed with or without liquid.
  • Oral Solution: Do not administer drops directly into the mouth. Drops must be given via a spoon and may be compatible with water, tea, or fruit juice.

Official Dosing and Titration Rules

The initial dosage is always low and must be increased gradually to find the effective maintenance dose. The dose should generally be increased in increments no sooner than every three days.

Condition Initial Daily Dose Dosing Frequency Maximum Daily Dose
Seizure Disorders (Adults/Adolescents age 10 years and older) 1.5 mg, divided Three doses per day 20 mg
Panic Disorder (Adults) 0.5 mg, divided Two doses per day 4 mg

If the doses are not equally divided, the largest dose should be taken at bedtime to help manage potential drowsiness.

Missed Doses and Discontinuation

If a dose is missed, take it as soon as possible, unless it is almost time for the next scheduled dose. Do not take a double dose to compensate. The medication must never be stopped abruptly; treatment discontinuation requires a gradual dose reduction (e.g., decreasing the daily dose by 0.125 mg every three days) to avoid withdrawal reactions. This tapering is a mandatory procedural step specified in the official use protocol.

Recent Clinical Evidence

Research Evidence / Overview of studies for Kriadex


Evidence for Use in Seizure Disorders and Epilepsy

Research exploring the use of Clonazepam for seizure disorders has relied on various study designs, including controlled trials comparing it to other active medicines, and systematic reviews that pool existing data. These studies typically monitored seizure frequency and severity. The available evidence supporting patterns observed in the studies is considered to be of low certainty. Research exploring short-term symptom changes for its use as a stand-alone treatment (monotherapy) is based on a limited number of small trials.

Evidence for this indication is limited, and follow-up durations were often limited. Importantly, high-quality, randomized, double-blind trials—a key measure of study rigor—are lacking when examining its use as an add-on therapy for certain complex, drug-resistant epilepsies. Therefore, low certainty is associated with consistent, long-term outcomes.


Evidence for Use in Panic Disorder

Clonazepam was evaluated in well-structured research, including randomized controlled trials (RCTs) against placebo and trials comparing it to other active medications commonly used for anxiety. These studies primarily focused on measuring the change in panic attack frequency and intensity, as well as the impact on functional limitations. The evidence base for short-term changes includes many controlled trials.

While the short-term evidence includes many controlled trials, there is limited information for long-term outcomes. Controlled data supporting maintenance of stability and continued observation beyond the initial several weeks of treatment are less extensive. Therefore, long-term effects are not fully established, and this area represents a research limitation.


What Is Still Uncertain About the Research for Kriadex

One significant research gap is the lack of high-quality comparative evidence for several uses. Evidence is limited and low certainty is associated with outcomes based on descriptive studies for involuntary motor symptoms, requiring confirmation from controlled trials. Long-term data are limited, and outcomes are not fully established by controlled trials across the medicine's main indications.

Frequently Asked Questions (FAQ)

Common questions about Kriadex (FAQ)


Q: How quickly should I expect to notice any effects from Kriadex?

According to official prescribing information, Kriadex is rapidly absorbed after ingestion. The maximum concentrations of the medicine in the bloodstream are typically reached within 1 to 4 hours.

Q: Does Kriadex start working right away, or does it take a few weeks?

While Kriadex is rapidly absorbed and reaches its highest level in the blood within a few hours, achieving a sustained therapeutic effect may require time. Official studies for conditions like seizure control sometimes noted a need for ongoing dosage adjustments to maintain consistent results over the longer term.

Q: If a side effect happens, does it usually go away after a while?

For some of the most common central nervous system side effects, such as drowsiness or fatigue, official patient information indicates they are often most prominent at the beginning of treatment. These effects may potentially lessen or improve after the first week or two as the body adjusts to the medication.

Q: Can Kriadex be used by older adults?

Official information notes that Kriadex can be used in older adults, as studies have not shown that age-specific problems inherently limit its application. However, older patients may have an increased sensitivity to effects like confusion and severe drowsiness, and careful dosage selection is therefore a consideration.

Q: Can alcohol be consumed while taking Kriadex?

Regulatory warnings indicate that alcohol use is advised against while using this medication. Combining alcohol with Kriadex can lead to enhanced central nervous system (CNS) depression, which increases the risk of severe effects like profound sedation and impaired coordination.

Q: Does Kriadex affect the liver or kidneys?

According to regulatory guidelines, Kriadex is officially stated as being contraindicated (not advised for use) in individuals with severe liver disease. Use requires caution in patients with other existing liver or kidney problems.

Q: Can Kriadex impact my ability to drive or operate machinery?

Official patient information warns that Kriadex may cause effects like drowsiness, unsteadiness, or difficulty concentrating. Regulatory guidance describes determining how the medicine affects a person as a necessary caution before engaging in activities like driving or operating machinery.

Q: How long does Kriadex stay in your system?

The length of time Kriadex remains in the system is described by its elimination half-life. The half-life, which is the time it takes for half of the dose to be eliminated from the body, is typically described as 30 to 40 hours.

Q: What kind of monitoring (tests) is required when taking Kriadex?

The need for routine laboratory monitoring is determined by the healthcare provider. Some official sources suggest that laboratory tests, such as complete blood counts or liver function tests, may be ordered to monitor the medicine’s effects on the body.

Q: Why is Kriadex only available by prescription?

Kriadex is classified by regulatory bodies as a Schedule IV controlled substance. This classification is due to the potential risks of abuse, misuse, addiction, and physical dependence, which require medical supervision for its use.

Q: Is Kriadex considered a strong medication?

The active ingredient in Kriadex, clonazepam, is officially classified as a high-potency benzodiazepine medication. This classification describes its profile within its pharmacological class.

Q: Is it true that Kriadex can cause trouble sleeping?

Although the medicine is known for its sedating effects, regulatory documents list difficulty falling or staying asleep (insomnia) as a potential side effect that may occur in some individuals.

Q: Is Kriadex the same type of drug as other popular treatments?

Kriadex belongs to the pharmacological class known as benzodiazepines. It is chemically related to other medicines used for similar indications that are also categorized within this class.

Q: What is the longest time Kriadex is typically taken for?

Regulatory research notes that the sustained effectiveness for some conditions, particularly seizure disorders, may be limited by the development of tolerance over the first few months of use. For panic disorder, effectiveness is established in short-term trials, but long-term outcomes are not yet fully established by controlled studies.

Q: Is there a risk of becoming dependent on Kriadex?

Official boxed warnings state that using Kriadex exposes users to the risks of abuse, misuse, addiction, and physical dependence. Physical dependence can develop even when the medicine is used exactly as prescribed and is taken for appropriate lengths of time.

Q: Does Kriadex have any documented risks during pregnancy or breastfeeding?

Regulatory guidance states that use during pregnancy is conditional, only permitted if the benefit is determined to outweigh the potential risks. Neonatal adverse reactions have been reported, and the drug is known to be excreted into human milk, with reported risks to the infant including sedation and weight loss.

Q: Has Kriadex been studied in children or teenagers?

Official documents confirm the medicine is approved for use in children 10 years and older for the treatment of certain seizure disorders. Studies have evaluated and found it effective for treating epilepsy in children, often at low levels in the bloodstream.

Q: Is Kriadex used for more than one medical condition?

Yes, regulatory documentation confirms that Kriadex has more than one approved use. It is indicated for the treatment of certain seizure disorders and for the management of panic disorder.

Q: Is Kriadex generally well-tolerated?

Clinical studies report that the medicine is associated with a high incidence of central nervous system effects. Drowsiness (somnolence) was reported in up to half of trial participants and was the most frequent adverse event leading patients to stop taking the treatment.

Q: What should I do if I feel like Kriadex is causing a serious problem?

Official patient instructions describe seeking immediate medical attention if serious symptoms occur, such as difficulty breathing, unresponsiveness, or signs of a serious reaction like rash or hives.

Q: Does the effectiveness of Kriadex change over time?

Studies of Kriadex for seizure disorders show that the body may develop tolerance to the effects, meaning that a loss of anticonvulsant activity has been observed in some individuals. This change in effectiveness was sometimes noted within the first three months of treatment.

Q: Is it a permanent treatment or a short-term one?

Treatment duration is determined by the healthcare provider. While Kriadex may be used for acute control and short-term situations, long-term use is associated with the risk of developing tolerance and dependence, which are important factors considered in the decision on treatment length.

Q: What has the FDA (or other regulatory body) said about the approval of Kriadex?

The FDA has approved Clonazepam tablets under an Abbreviated New Drug Application (ANDA). This approval allows the medicine to be marketed for the management of certain seizure disorders and panic disorder.

Q: Is the medication known to cause weight changes?

While weight change itself is not listed as a common side effect in regulatory documents, an increase in appetite has been noted as a potential adverse reaction in the official product information.

Q: How does Kriadex interact with herbal supplements?

Official patient guidance emphasizes that individuals should inform their healthcare provider about all substances being taken, which includes herbal supplements. This transparency allows for the proper assessment and management of any potential interactions between Kriadex and other products.

Q: Are there genetic factors that affect how Kriadex works?

Regulatory documents on pharmacokinetics note that the processing of the drug, called biotransformation, occurs mainly in the liver. A group of enzymes, including Cytochrome P-450 (CYP3A), plays an important role in how the drug is metabolized by the body.

Q: Is Kriadex known to cause mood changes?

Official side effect listings include a range of changes in mental health and mood. These may include new or worsening anxiety, depression, increased irritability, or, in rare cases, suicidal thoughts.

Q: Does Kriadex affect blood pressure?

Regulatory information notes that blood pressure changes are associated with the sudden cessation of Kriadex. Abruptly stopping the medication can result in withdrawal symptoms, which may include alterations in blood pressure.

Q: What if Kriadex makes me feel worse?

If the medication causes unexpected changes in mood or behavior, such as worsening depression, aggressive behavior, or suicidal thoughts, official sources indicate that patients should discuss this with their healthcare provider.

Q: Is Kriadex linked to any specific long-term health risks?

Studies and official information indicate that long-term use of benzodiazepines is associated with certain risks. These include a greater risk of developing physical dependence, tolerance, and potential problems with memory, cognitive function, and muscle coordination.

Q: Why are there different strengths of Kriadex tablets available?

The manufacturing of Kriadex in multiple tablet strengths is necessary to align with the official guidelines for use. This provides the flexibility needed for the mandatory gradual adjustment of dosage (titration) and to reach the varying effective maintenance doses required for different approved conditions.

How should Kriadex be stored and disposed of?

How to Store Kriadex (Clonazepam)

Kriadex tablets must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F). The medication must be kept in a tightly closed container to protect it from both light and moisture.

As a controlled substance, Kriadex must be stored in a safe place to prevent unauthorized access. It is strictly required to keep the medicine out of the reach of children.

Disposal Requirements

Unused or expired Kriadex must be properly discarded and should not be kept. Patients are officially instructed to ask a healthcare professional or pharmacist for guidance on the proper disposal of unused medicine, ensuring compliance with all applicable local, regional, and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kriadex found in:

A-Z Index: